Source link : https://www.newshealth.biz/health-news/fda-oks-subcutaneous-daratumumab-plus-vrd-for-myeloma/
The FDA approved subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant, the agency announced Tuesday. Approval was based on results from the phase III PERSEUS trial, which evaluated 709 patients […]
Author : News Health
Publish date : 2024-07-31 15:09:45
Copyright for syndicated content belongs to the linked Source.
Categories